Page 2510 - Williams Hematology ( PDFDrive )

2481
2480 Index Index 2481

spent phase, 1301 etiology and pathogenesis, 892–896 Pre-B cell, 270
hematopoietic cell transplantation, hepatoerythropoietic, 889, 905, 906, 909. Precursor (immature) B-cell acute
1301 See also Porphyria cutanea tarda lymphoblastic leukemia, 183, 184t,
splenectomy, 1301 (PCT) 186f, 1515–1517, 1521t
for thrombosis or bleeding, 2081 hereditary coproporphyria, 890t, 904–905 Precursor (immature) B-cell lymphomas/
Polyglandular autoimmune (PGA) syndrome, intermittent. See Acute intermittent leukemias, 1494t, 1592
87 porphyria (AIP) Precursor B cells, 1151, 1168
Poly-Ig receptor, 1161 laboratory features, 890t Precursor cells, in erythropoiesis, 482f, 482t,
Polymerase chain reaction (PCR), 152, 1716 porphyria cutanea tarda. See Porphyria 483, 483f
Polymorphisms, 147 cutanea tarda (PCT) Precursor (immature) T-cell lymphomas/
Polymorphonuclear leukocytosis, 997. See variegate, 904–905 leukemias, 1498t, 1592, 1592f
also Neutrophilia X-linked coproporphyria, 889, 890t, 891t Precursor thymocytes, 1179
Polymorphonuclear neutrophils (PMN), 940f Porphyrin precursors, 891t Prednisolone
Polyphosphate-4-phosphatase (P4P), 1817 Porphyrins, 889, 891t for acute lymphoblastic leukemia, 1515
Polyposis coli, 1654 in congenital erythropoietic porphyria, 897 adverse effects, 1519t
Pomalidomide, 333–335 in hepatoerythropoietic porphyria, for antiphospholipid syndrome in
adverse effects, 335 905–906 pregnancy, 2245
for AL amyloidosis, 1761, 1781 in hereditary coproporphyria, 905–906 for immune thrombocytopenia, 2004
mechanism of action, 333–334 in porphyria cutanea tarda, 905–906 for Langerhans cell histiocytosis, 1107
for myeloma, 1753t, 1754 Portal hypertension, in primary for NK/T-cell lymphoma, 1702
pharmacology, 334 myelofibrosis, 1324–1325 for α-heavy-chain disease, 1808
structure, 333f Portal-systemic vascular shunt surgery, for for μ-heavy-chain disease, 1810
Ponatinib primary myelofibrosis, 1330 Prednisone. See also BEACOPP regimen;
adverse effects, 339t, 341, 1451t, 1458 Portal vein thrombosis, 2195 CHOP regimen; COPP regimen;
for chronic myelogenous leukemia, 339t, Portland hemoglobin, 101, 101t, 728, 747 EPOCH regimen; MOPP regimen;
1454, 1458, 1466 Posaconazole, 385, 387t, 389, 1397 Stanford V regimen
comparison with other tyrosine kinase Positive regulatory domain 1-binding for acute lymphoblastic leukemia, 1515
inhibitors, 1451t factor-1 (PRDM1), 1171–1172 for adult Langerhans cell histiocytosis,
drug interactions, 339t, 1451t Positron emission tomography (PET). See 1108
pharmacology, 339t, 340 FDG-PET adverse effects, 1519t
structure, 340f Postpartum hemorrhage, 1987, 2137, 2138 for AL amyloidosis, 1779–1780
Popcorn cells, 1600, 1601f Postthrombotic syndrome, 2273 for α-heavy-chain disease, 1808
Porcine factor VIII, 2185 Posttransfusion purpura (PTP), 2359, 2361 for autoimmune hemolytic anemia, 838
Porphobilinogen (PBG), 889, 891f, 903 Posttranslational effects, aging and, 130–131 for chronic lymphocytic leukemia,
Porphobilinogen deaminase (PBGD), 701t, Posttransplant lymphoproliferative disorders 1534–1535
894 (PTLD), 1265–1266, 1500t, 1574, for diffuse large B-cell lymphoma,
Porphobilinogen (PBG) synthase, 894, 918 1636 1629t
Porphyria cutanea tarda (PCT), 905–908 Potassium chlorate, 810 for follicular lymphoma, 1645t, 1646
clinical features, 643, 890t, 907, 907f PP1R12C, 444 for γ-heavy-chain disease, 1806
definition, 905 PPAR (peroxisome proliferator-activated for graft-versus-host disease, 372
diagnosis, 907–908 receptor), 197, 452, 1873–1874 for immune thrombocytopenia, 2004
enzymes affected by, 890t, 891f PPBL (persistent polyclonal lymphocytosis of for Langerhans cell histiocytosis, 1107
laboratory features, 891t B lymphocytes), 1200–1202, 1201f for large granular lymphocytic leukemia,
pathogenesis of clinical findings, 906–907 PPO (protoporphyrinogen oxidase), 895 1567
pathophysiology, 905–906 PR1 vaccine, 423 lenalidomide and, 334
therapy, 908–909 Pracinostat, 240 for mononucleosis, 1269
Porphyrias, 889–909 Pralatrexate, 1687, 1696t for mycosis fungoides, 1688
δ-aminolevulinate dehydratase (ADP), Prasugrel for myeloma, 1751, 1752t
894, 900 for acute coronary syndromes, 2076 for primary myelofibrosis, 1328
congenital. See Congenital erythropoietic antiplatelet effects, 404t, 405 thalidomide and, 334
porphyria (CEP) for sickle cell disease, 777t for Waldenström macroglobulinemia,
definition and history, 889–890 PRAT4A, 296, 296f 1793, 1794–1795
enzyme defects in, 890t, 891f Praziquantel, 604 Preeclampsia, 2011–2012, 2210–2211
erythropoietic protoporphyria. See PRDM1, 234t, 1171, 1737, 1786 Prefibrotic primary myelofibrosis, 1323t,
Erythropoietic protoporphyria PRDM1 (positive regulatory domain 1324
(EPP) 1-binding factor-1), 1171–1172 p region, 1166

Kaushansky_index_p2393-2506.indd 2481 9/21/15 3:22 PM